Rhythm Pharmaceuticals (RYTM) News Today $52.80 -1.75 (-3.21%) (As of 09/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 Time Period Jennifer L. Good Sells 31,751 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) StockSeptember 20 at 8:32 AM | insidertrades.comRhythm Pharmaceuticals (NASDAQ:RYTM) Sets New 52-Week High at $54.88September 20 at 7:39 AM | americanbankingnews.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) to Post Q3 2024 Earnings of ($0.73) Per Share, HC Wainwright ForecastsRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) - Stock analysts at HC Wainwright issued their Q3 2024 earnings estimates for shares of Rhythm Pharmaceuticals in a report issued on Wednesday, September 18th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earninSeptember 20 at 6:12 AM | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Director Sells $1,663,752.40 in StockSeptember 19 at 6:37 PM | americanbankingnews.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Director Jennifer L. Good Sells 31,751 SharesRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) Director Jennifer L. Good sold 31,751 shares of the stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $52.40, for a total transaction of $1,663,752.40. Following the sale, the director now owns 3,000 shares of the company's stock, valued at approximately $157,200. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.September 19 at 6:35 PM | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Shares Up 6.1%September 19 at 8:36 AM | americanbankingnews.comRhythm Pharmaceuticals (NASDAQ:RYTM) Research Coverage Started at HC WainwrightSeptember 19 at 4:47 AM | americanbankingnews.comHC Wainwright & Co. Initiates Coverage of Rhythm Pharmaceuticals (RYTM) with Buy RecommendationSeptember 19 at 3:06 AM | msn.comRhythm Pharmaceuticals (NASDAQ:RYTM) Hits New 12-Month High at $54.88Rhythm Pharmaceuticals (NASDAQ:RYTM) Hits New 1-Year High at $54.88September 18 at 12:27 PM | marketbeat.comWhat 4 Analyst Ratings Have To Say About Rhythm PharmaceuticalsSeptember 18 at 11:57 AM | benzinga.comJMP Securities Initiates Coverage of Rhythm Pharmaceuticals (RYTM) with Market Outperform RecommendationSeptember 18 at 11:57 AM | msn.comRhythm Pharma draws bullish view at JMP on opportunity in rare genetic obesitiesSeptember 18 at 11:57 AM | msn.comRhythm Pharmaceuticals (NASDAQ:RYTM) Coverage Initiated at HC WainwrightHC Wainwright started coverage on Rhythm Pharmaceuticals in a research report on Wednesday. They issued a "buy" rating and a $64.00 price target for the company.September 18 at 8:10 AM | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Coverage Initiated at JMP SecuritiesSeptember 18 at 4:59 AM | americanbankingnews.comRhythm Pharmaceuticals (NASDAQ:RYTM) Trading Up 6.1%Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading Up 6.1%September 17 at 3:16 PM | marketbeat.comHow dog dancing duo Roni & Rhythm took their paw-inspiring act to the next step on 'America's Got Talent'September 17 at 1:03 PM | yahoo.comBuy Rating Affirmed for Rhythm Pharmaceuticals Amid Strong Market Position and Promising PipelineSeptember 17 at 1:03 PM | markets.businessinsider.comRhythm Pharmaceuticals (NASDAQ:RYTM) Receives New Coverage from Analysts at JMP SecuritiesJMP Securities started coverage on Rhythm Pharmaceuticals in a research report on Tuesday. They issued an "outperform" rating and a $64.00 price target on the stock.September 17 at 8:22 AM | marketbeat.comPrimecap Management Co. CA Sells 435,200 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Primecap Management Co. CA decreased its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 5.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,312,391 sSeptember 17 at 6:51 AM | marketbeat.comOur Rhythm, Our Voices shines light on Latin American immigrant life through soulful songsSeptember 16, 2024 | msn.comRhythm Pharmaceuticals Announces New Employment Inducement GrantsSeptember 16, 2024 | globenewswire.comBristol Rhythm and Roots Reunion brings people together for music and funSeptember 15, 2024 | msn.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Director Sells $868,924.65 in StockSeptember 14, 2024 | americanbankingnews.comRhythm & Roots, Umoja Festival, Learn to Fly event and more | Weekend events in the Tri-CitiesSeptember 13, 2024 | yahoo.comInvestors Purchase Large Volume of Call Options on Rhythm Pharmaceuticals (NASDAQ:RYTM)September 13, 2024 | americanbankingnews.comAnalysts Set Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Target Price at $55.83September 13, 2024 | americanbankingnews.comPamela J. Cramer Sells 4,099 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) StockSeptember 12, 2024 | insidertrades.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells $205,072.97 in StockRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) insider Pamela J. Cramer sold 4,099 shares of Rhythm Pharmaceuticals stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $50.03, for a total value of $205,072.97. Following the completion of the sale, the insider now owns 13,500 shares of the company's stock, valued at $675,405. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.September 11, 2024 | marketbeat.comRhythm Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:RYTM)Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) was the recipient of some unusual options trading activity on Wednesday. Stock investors purchased 3,047 call options on the stock. This represents an increase of 988% compared to the typical daily volume of 280 call options.September 11, 2024 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stake Raised by Bank of New York Mellon CorpBank of New York Mellon Corp lifted its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 14.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 191,871 shares of the company's stocSeptember 11, 2024 | marketbeat.com‘Rhythm City’ star Bra Kop opens up about family rejection due to his Zimbabwean wifeSeptember 10, 2024 | msn.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Average Rating of "Moderate Buy" from BrokeragesShares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six analysts that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and five haveSeptember 10, 2024 | marketbeat.com271,398 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Bought by Candriam S.C.A.Candriam S.C.A. purchased a new position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 271,398 shares of the companSeptember 9, 2024 | marketbeat.comNational Bank of Canada FI Boosts Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)National Bank of Canada FI increased its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 10.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 404,242 shares of the company's stock after buyingSeptember 8, 2024 | marketbeat.comJGP Global Gestao de Recursos Ltda. Reduces Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)JGP Global Gestao de Recursos Ltda. lessened its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 94.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,814 shSeptember 5, 2024 | marketbeat.comLow Flying Hawks Announce New Album Featuring Rhythm Section of Melvins’ Dale Crover and Mr. Bungle’s Trevor DunnAugust 30, 2024 | yahoo.comRhythm: Pivotal Moment Approaching In Hypothalamic Obesity (Rating Upgrade)August 30, 2024 | seekingalpha.comInsider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells 3,200 Shares of StockAugust 29, 2024 | insidertrades.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Director Lynn A. Tetrault Sells 4,300 SharesAugust 29, 2024 | insidertrades.comRhythm Pharma: FDA To Review Supplemental New Drug Application For IMCIVREE - Quick FactsAugust 28, 2024 | markets.businessinsider.comRhythm Pharmaceuticals (NASDAQ:RYTM) Shares Up 7.9%Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Up 7.9%August 26, 2024 | marketbeat.comRhythm Pharma Gets FDA Priority Review of Obesity Drug for ChildrenAugust 26, 2024 | marketwatch.comRhythm Pharmaceuticals to Present at Wells Fargo Healthcare Conference in SeptemberAugust 26, 2024 | markets.businessinsider.comRhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) in Patients as Young as 2 years oldAugust 26, 2024 | globenewswire.comSamsung Galaxy watches in India get ‘Irregular Heart Rhythm Notification’ featureAugust 22, 2024 | msn.comTickets on sale for Reno Rodeo Foundation’s annual Rhythm and Rawhide fundrasierAugust 21, 2024 | msn.comRhythm and Alps 2024: First line-up includes Becky Hill, Shapeshifter, Sir Dave Dobbyn and moreAugust 21, 2024 | msn.comNisa Investment Advisors LLC Boosts Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Nisa Investment Advisors LLC raised its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 157.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 374,347 shares of the company's stAugust 20, 2024 | marketbeat.comGRAAHI Rhythm Run 5K and Health Fair returns to MLK Park on August 17August 17, 2024 | yahoo.comAssenagon Asset Management S.A. Sells 56,160 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Assenagon Asset Management S.A. lessened its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 19.7% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 229,491 shares of the company's stock after seAugust 17, 2024 | marketbeat.com Get Rhythm Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter. Email Address Must-Know for Trading Options (Ad)Options are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a row! But – knowing what the options trading landscape looks like, and what you're up against is a must. So make sure you claim your free seat by clicking here now. RYTM Media Mentions By Week RYTM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RYTM News Sentiment▼0.350.49▲Average Medical News Sentiment RYTM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RYTM Articles This Week▼286▲RYTM Articles Average Week Get Rhythm Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Arvinas News Today Pliant Therapeutics News Today Annexon News Today Theravance Biopharma News Today Sarepta Therapeutics News Today Catalent News Today Qiagen News Today Legend Biotech News Today Roivant Sciences News Today Ascendis Pharma A/S News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RYTM) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in SeptemberWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make ...Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHow the US Will Win the Great Lithium RaceChina spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but i...DealMaker | SponsoredThe Perfect Storm for an EV RevoltWith constant talk about Artifical Intelligence, inflation, and the upcoming election clogging the airwaves......Eagle Publishing | SponsoredTrump’s “Tax Free” Retirement StrategySince 1924 — over one hundred years — the US dollar has lost nearly 18x its value. If you're planning on re...Gold Safe Exchange | SponsoredThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt i...InvestorPlace | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rhythm Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
